What Is a ‘Tolerable’ Dose? AACR-Industry Roundtable 2025 Examines Dose Optimization
Experts discussed challenges and opportunities for dose optimization of cancer treatments at the 2025 AACR-Industry Roundtable.
Experts discussed challenges and opportunities for dose optimization of cancer treatments at the 2025 AACR-Industry Roundtable.
The blog rounds up the 2023 SABCS, which had 10,874 in-person and virtual registrants and featured cutting-edge research, thoughtful...
What experts forecast for cancer research and treatment in 2024. Part 1: Catherine J. Wu, MD, FAACR, on...
Highlights of December 2023 AACR journals include clinical trial results, strategies to improve therapy, and a new cervical cancer...
Charles Swanton, MD, PhD, FAACR, spoke on the role chromosomal instability plays in breast cancer evolution.
In the final quarter of 2023, the FDA issued 17 approvals specifically for the treatment of tumors.
“What will you do Monday morning?” was the question posed by the final session on the final full day...
In 1994, at the age of 40, Ginny Mason, RN, began noticing some concerning differences in the size and...
In 2022, AACR launched a unique initiative called AACR Maximizing Opportunity for New Advancements in Research in Cancer (MONARCA)...
Studies featured at this year’s San Antonio Breast Cancer Symposium (SABCS) suggest that—in some situations—adjuvant radiotherapy may not be...
A breast cancer diagnosis can pose innumerable challenges, and with the average age at diagnosis dropping, the impact of...